Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients

Journal of Clinical Oncology

Volumn 16, Issue 11, 1998, Pages 3493-3501

  Shapiro, Charles L ^a   Hardenbergh, Patricia Harrigan ^a   Gelman, Rebecca ^a   Blanks, Dana ^a   Hauptman, Paul ^a   Recht, Abram ^a   Hayes, Daniel F ^a   Harris, Jay ^a   Henderson, I Craig ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 0031792641     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.11.3493     Document Type: Article

References (56)

1. Shan K, Lincoff M, Young JB: Anthracycline-induced cardiotoxicity. Ann Intern Med 125:47-58, 1996
2. Buzdar AU, Marcus C, Smith TL, et al: Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55:2761-2765, 1985
3. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710, 1979
4. Praga C, Beretta G, Vigo PL, et al: Adriamycin cardiotoxicity: A survey of 1273 patients. Cancer Treat Rep 63:827-834, 1979
5. Lipshultz SE, Colan SD, Gelber RD, et al: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-815, 1991
6. Steinerz LJ, Steinherz PG, Tan CTC, et al: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J Am Med Assoc 266:1672-1677, 1991
7. Kannel WB, Hjortland MC, McNamara PM, et al: Menopause and risk of cardiovascular disease: The Framingham study. Ann Intern Med 85:447-752, 1976
8. Dresdale A, Bonow RO, Wesley R, et al: Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 52:51-60, 1983
9. Sutton GP, Stehman FB, Einhorn LH, et al: Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 7:223-229, 1989
10. Ibrahim NK, Frye D, Buzdar AU, et al: Risk of doxorubicin (D)-related cardiac morbidity in elderly patients (PTS.) With metastatic breast cancer (MBC). Arch Intern Med 156:882, 1996 (abstr)
11. Armitage JO, Fyfe AE, Lewis J: Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J Clin Oncol 2:898-902, 1984
12. Shapiro CL, Henderson IC, Gelman RS, et al: A randomized trial of 15 vs 30 weeks (wks) of adjuvant chemotherapy in high risk breast cancer patients: Results after a median follow-up of 9.1 years. Proc Am Soc Clin One 10:44, 1991 (abstr)
13. Henderson IC, Gelman RS, Harris JR, et al: Duration of therapy in adjuvant chemotherapy trials. NCI Monogr 1:95-98, 1986
14. Griem KL, Henderson IC, Gelman R, et al: The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J Clin Oncol 5:1549-1555, 1987
15. Gynes GG, Gagliardi G, Lax I, et al: Evaluation of irradiated heart volume in stage I breast cancer patients treated with postoperative adjuvant radiotherapy. J Clin Oncol 15:1348-1353, 1997
16. Rutqvist LE, Lax I, Forander T, et al: Cardiovascular mortality in a randomized trial of adjuvant radiotherapy versus surgery alone in primary breast cancer. Int J Radiat Biol Phys 22:887-896, 1992
17. Nixon AJ, Manola J, Gelman R, et al: No long term increase in cardiac-related mortality after breast-conserving surgery and radiation therapy using modern techniques. J Clin Oncol 16:1374-1379, 1998
18. Rosner B: Fundamentals of Biostatistics (ed 3). Boston, MA, PWS-Kent, 1990
19. Ingelfinger JA, Mosteller F, Thibodeau LA, et al: Biostatistics in Clinical Medicine. New York, NY, Macmillan, 1983
20. Santner TJ, Duffy DE: The Statistical Analysis of Discrete Data. New York, NY, Springer-Verlag, 1989
21. Chatterjee S, Price B: Regression Analysis by Example (ed 2). New York, NY, Wiley, 1991
22. US Department of Health and Human Services. The Framingham Heart Study: An Epidemiologic Investigation of Cardiovascular Disease. Bethesda, MD, United States Department of Health and Human Services, 1987
23. Dawson-Saunders B, Trapp RG: Basic and Clinical Biostatistics. Norwalk, CT, Appleton & Lange, 1990
24. Budzar AU, Kau SW, Smith TL, et al: Ten-year results of FAC adjuvant chemotherapy in breast cancer. Am J Clin Oncol 12:123-128, 1989
25. Ettinghausen SE, Bonow RO, Palmeri St, et al: Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas. Arch Surg 121:1445-1451, 1986
26. Yamashita J-I, Ogawa M, Shirakusa T: Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity. Int J Cancer 62: 542-547, 1995
27. Hortobagyi GN, Buzdar AU, Marcus CE, et al: Immediate and long-term toxieity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr 1:105-109, 1986
28. Fisher B, Redmond D, Wickerham L, et al: Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 7:572-582, 1989
29. Buzzoni R, Bonadonna G, Valagussa P, et al: Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 9:2134-2140, 1991
30. Valagussa P, Zambetti M, Biasi S, et al: Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol 5:209-216, 1994
31. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. J Am Med Assoc 273:542-547, 1995
32. Blomqvist C, Tiusanen K, Elomaa I, et al: The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-fluorouracil) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomized trial. Br J Cancer 66:1171-1176, 1993
33. Saarto T, Blomqvist C, Tiusanen K, et al: The prognosis of stage III breast cancer treated with post-operative radiotherapy and Adriamycin-based chemotherapy with and without tamoxifen. Eight year follow up results of a randomized trial. Eur J Surg Oncol 21:146-150, 1995
34. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
35. Somers R, Carde P, Henry-Amar M, et al: A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 12:279-287, 1994
36. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and rluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumor: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
37. Ferme C, Lepage E, Brice P, et al: Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: Results of a prospective clinical trial with 70 stage IIIB-IV patients, Int J Radiat Oncol Biol Phys 26:397-405, 1993
38. Brusamolino E, Orlandi E, Morrra E, et al: Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy. Ann Oncol 5:S53-S57, 1994 (suppl 2)
39. Cullen MH, Stuart NSA, Woodroffe C, et al: Ch1VPP/PABIOE and radiotherapy in advanced Hodgkin's disease. J Clin Oncol 12:779-787, 1994
40. Canellos GP, Petroni GR, Barcos M, et al: Etoposide, vinblastine and doxoruhicin: An active regimen for the treatment of Hodgkin's disease in relapse following MOPP. J Clin Oncol 13:2005-2011, 1995
41. Viviani S, Bonadonna G, Santoro A, et al: Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results. J Clin Oncol 14:1421-1430, 1996
42. Colonna P, Jais J-P, Desablens B, et al: Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: Ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. J Clin Oncol 14:1928-1935, 1996
43. Corn BW, Trock BJ, Goodman RL: Irradiation-related dischemic heart disease. J Clin Oncol 8:741-750, 1990
44. McEniery PT, Dorosti K, Schiavone WA, et al: Clinical angiographic features of coronary artery disease after chest irradiation. Am J Cardiol 60:1021-1024, 1987
45. Hancock SL, Tucker MA, Hopp RT: Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. J Am Med Assoc 270:1949-1955, 1993
46. Haybittle JL, Brinkley D, Houghton D, et al: Postoperative radiotherapy and late mortality: Evidence from the Cancer Research Campaign trial for early breast cancer. Br Med J 298:1611-1614, 1989
47. Host H, Brenhovd IO, Loeb M: Postoperative radiotherapy in breast cancer-Long-term results from the Oslo study. Int J Radiat Oncol Bio Phys 12:727-732, 1986
48. Jones JM, Ribeiro GG: Mortality patterns over 34 years of breast cancer patients in a clinical trial of post-operative radiotherapy. Clin Radiol 40:204-208, 1989
49. Fuller SA, Haybittle JL, Smith RFA, et al: Cardiac doses in post-operative breast irradiation. Radiat Oncol 25:19-24, 1992
50. Harris JR, Hellman S: Put the "hockey stick" on ice. Int J Radiat Oncol Biol Phys 15:497-499, 1988
51. Plukett ME, Bornstein BA, Costello P, et al: Use of spiral CT in the assessment of cardiac structures for planning 3D volumetric RT treatment of the breast. Radiology 189:355-358, 1993
52. Recht A: Radiotherapy-chemotherapy integration in breast-conservation therapy, in Meyer JL (ed): Frontiers of Radiation Therapy and Oncology: Selection Criteria for Conservative Cancer Management. Basel, Sweden, Karger, 1993, pp 89-102
53. Pandya K, Olson J, Neuberg D: Observations on cardiac toxicity in a treatment program containing Adriamycin and radiation therapy for stage III breast cancer: An Eastern Cooperative Oncology Group study. Br Cancer Res Treat 14:148a, 1989 (abstr)
54. Blomquist C, Tiusanen K, Elomaa I, et al: The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicinftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomized trial. Br J Cancer 66:1171-1176, 1993
55. Ragaz J, Jackson SM, Le N, et al: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956-962, 1997
56. Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337:949-955, 1997